Impact of ureido/carboxypenicillin resistance on the prognosis of ventilator-associated pneumonia due to Pseudomonas aeruginosa

[1]  Egon A. Ozer,et al.  The Accessory Genome of Pseudomonas aeruginosa , 2010, Microbiology and Molecular Biology Reviews.

[2]  S. Lynch,et al.  Secretion of Pseudomonas aeruginosa type III cytotoxins is dependent on pseudomonas quinolone signal concentration. , 2010, Microbial pathogenesis.

[3]  J. Carlet,et al.  Quorum sensing-dependent virulence during Pseudomonas aeruginosa colonisation and pneumonia in mechanically ventilated patients , 2010, Thorax.

[4]  Elie Azoulay,et al.  Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models , 2010, Intensive Care Medicine.

[5]  Nancy D. Hanson,et al.  Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms , 2009, Clinical Microbiology Reviews.

[6]  Yves Cohen,et al.  Predicting the risk of documented ventilator-associated pneumonia for benchmarking: Construction and validation of a score* , 2009, Critical care medicine.

[7]  Mauricio Valencia,et al.  Ventilator-associated pneumonia , 2009, Current opinion in critical care.

[8]  T. Nakae,et al.  Macrolide Antibiotic-Mediated Downregulation of MexAB-OprM Efflux Pump Expression in Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.

[9]  C. van Delden,et al.  Resistance and Virulence of Pseudomonas aeruginosa Clinical Strains Overproducing the MexCD-OprJ Efflux Pump , 2008, Antimicrobial Agents and Chemotherapy.

[10]  E. Bingen,et al.  Pseudomonas aeruginosa May Accumulate Drug Resistance Mechanisms without Losing Its Ability To Cause Bloodstream Infections , 2007, Antimicrobial Agents and Chemotherapy.

[11]  J. Rello,et al.  Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy* , 2007, Critical care medicine.

[12]  C. van Delden,et al.  Development and Persistence of Antimicrobial Resistance in Pseudomonas aeruginosa: a Longitudinal Observation in Mechanically Ventilated Patients , 2007, Antimicrobial Agents and Chemotherapy.

[13]  M. Wolff,et al.  Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia , 2006, Intensive Care Medicine.

[14]  Yehuda Carmeli,et al.  Multidrug-Resistant Pseudomonas aeruginosa: Risk Factors and Clinical Impact , 2006, Antimicrobial Agents and Chemotherapy.

[15]  C. Clec’h,et al.  Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  M. Kollef,et al.  Pseudomonas aeruginosa Bloodstream Infection: Importance of Appropriate Initial Antimicrobial Treatment , 2005, Antimicrobial Agents and Chemotherapy.

[17]  F. Rojo,et al.  Overexpression of the Multidrug Efflux Pumps MexCD-OprJ and MexEF-OprN Is Associated with a Reduction of Type III Secretion in Pseudomonas aeruginosa , 2005, Journal of bacteriology.

[18]  Corinne Alberti,et al.  Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity , 2004, Intensive Care Medicine.

[19]  J. Timsit,et al.  Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  S. Ridley,et al.  Drugs in anaesthesia , 2003, Anaesthesia.

[21]  Nnis System.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. , 2003, American journal of infection control.

[22]  M. Oh,et al.  Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  T. Crabtree,et al.  Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients , 2003, Critical care medicine.

[24]  F. Baquero,et al.  Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. , 2002, The Journal of antimicrobial chemotherapy.

[25]  Corinne Alberti,et al.  Calibration and discrimination by daily Logistic Organ Dysfunction scoring comparatively with daily Sequential Organ Failure Assessment scoring for predicting hospital mortality in critically ill patients* , 2002, Critical care medicine.

[26]  R. Hancock,et al.  Multidrug Efflux Systems Play an Important Role in the Invasiveness of Pseudomonas aeruginosa , 2002, The Journal of experimental medicine.

[27]  D. De Bacquer,et al.  Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  A. Combes,et al.  Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  J. Rello,et al.  Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. , 2002, Critical care medicine.

[30]  A. Harris,et al.  Risk Factors for Piperacillin-Tazobactam-Resistant Pseudomonas aeruginosa among Hospitalized Patients , 2002, Antimicrobial Agents and Chemotherapy.

[31]  R. Auckenthaler,et al.  Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Ronald N. Jones,et al.  Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  J. Vincent.  Microbial resistance: lessons from the EPIC study , 2000, Intensive Care Medicine.

[34]  Y. Carmeli,et al.  Emergence of Antibiotic-Resistant Pseudomonas aeruginosa: Comparison of Risks Associated with Different Antipseudomonal Agents , 1999, Antimicrobial Agents and Chemotherapy.

[35]  M. Gambello,et al.  Expression of Pseudomonas aeruginosa virulence genes requires cell-to-cell communication. , 1993, Science.

[36]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[37]  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. , 2004, American journal of infection control.

[38]  J. Vincent.  Microbial resistance: lessons from the EPIC study. European Prevalence of Infection. , 2000, Intensive care medicine.

[39]  S. Lemeshow,et al.  A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. , 1993, JAMA.